Person · CIK 1614740

Christopher Peetz

CHIEF EXECUTIVE OFFICER at Mirum Pharmaceuticals; director at Arcutis Biotherapeutics

Earlier: Alpine Immune Sciences and Tobira Therapeutics

Source: Forms 3, 4, 5 and 144 on SEC EDGAR

Sold on Form 4$27.6M

Noticed on Form 144$24M

Bought on Form 4$314K

Companies4

Holdings now

As reported after the latest Form 3, 4 or 5 at each company.

How these figures work

Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.

Company	Security	Held	Shares or units	As of
Mirum Pharmaceuticals MIRM	Common Stock	Directly	206,637	Nov 4, 2026 · Filing · EDGAR
Mirum Pharmaceuticals MIRM	Common Stock	By The Peetz Family Trust	187,500	Nov 4, 2026 · Filing · EDGAR
Mirum Pharmaceuticals MIRM	Employee Stock Option (right to buy) exercise $2.94, expires Mar 11, 2029, into Common Stock	Directly	38,487	Nov 4, 2026 · Filing · EDGAR
Arcutis Biotherapeutics ARQT	Common Stock	Directly	4,315	Jul 15, 2026 · Filing · EDGAR
Arcutis Biotherapeutics ARQT	Common Stock	By The Peetz Family Trust	187,500	Jul 15, 2026 · Filing · EDGAR
Arcutis Biotherapeutics ARQT	Stock Option (right to buy) exercise $27.78, expires Jul 15, 2036, into Common Stock	Directly	21,486	Jul 15, 2026 · Filing · EDGAR
Arcutis Biotherapeutics ARQT	Stock Option (right to buy) exercise $27.78, expires Jul 15, 2036, into Common Stock	Directly	13,010	Jul 15, 2026 · Filing · EDGAR
Alpine Immune Sciences	Common Stock	Christopher Peetz & Christine Peetz TR UA 02/15/2017 The Peetz Living Trust	1,900	Sep 23, 2021 · Filing · EDGAR
Alpine Immune Sciences	Common Stock	Christopher Peetz and Christine Peetz TR UA 02/15/2017 The Peetz Living Trust	1,900	Sep 23, 2021 · Filing · EDGAR

Sold and noticed by quarter

Sold (Form 4) Noticed (Form 144) Bought (Form 4)

Quarterly totals as a table

Quarter	Sold (Form 4)	Noticed (Form 144)	Bought (Form 4)
Q4 2026	$1.8M	$1.8M	—
Q3 2026	$7.4M	$7.4M	—
Q2 2026	$2.9M	$2.9M	—
Q1 2026	$6M	$5.4M	—
Q3 2025	$4.7M	$4.7M	—
Q1 2025	$4.2M	$1.9M	—
Q1 2024	$304K	—	—
Q3 2023	$141K	—	—
Q1 2023	$106K	Not machine-readable	—
Q4 2021	$71K	Not machine-readable	$101K
Q3 2021	—	—	$19K
Q4 2020	—	—	$93K
Q3 2019	—	—	$100K

Form 144 notices went onto EDGAR as structured data on April 13, 2023. Earlier notices were filed on paper and cannot be read here, so those quarters show no noticed amount.

Planned sales (Form 144) and the sales that followed

Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.

How we match

A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.

Notice date	Noticed	Planned sale	Outcome	Links
Mirum Pharmaceuticals MIRM · Morgan Stanley Smith Barney · 10b5-1 plan adopted Mar 2, 2026 · 5 notices
Nov 4, 2026	20,000 · ~$1.8M	Nov 4, 2026	Sold as noticed Sold 20,000 at $90.00 on Nov 4 · $1.8M Form 4	Filing · EDGAR
Sep 1, 2026	30,000 · ~$3M	Sep 1, 2026	Sold as noticed Sold 30,000 in 2 sales, Sep 1 to Sep 1 · $3M Form 4	Filing · EDGAR
Aug 10, 2026	20,000 · ~$2M	Aug 10, 2026	Sold as noticed Sold 20,000 in 3 sales, Aug 10 to Aug 10 · $2M Form 4	Filing · EDGAR
Jul 6, 2026	20,000 · ~$2.4M	Jul 6, 2026	Sold as noticed Sold 20,000 in 4 sales, Jul 6 to Jul 6 · $2.4M Form 4	Filing · EDGAR
Jun 1, 2026	30,000 · ~$2.9M	Jun 1, 2026	Sold as noticed Sold 30,000 in 6 sales, Jun 1 to Jun 1 · $2.9M Form 4	Filing · EDGAR
Mirum Pharmaceuticals MIRM · Morgan Stanley Smith Barney · 10b5-1 plan adopted Jan 31, 2023 · 2 notices
Mar 17, 2026	40,985 · ~$3.8M	Mar 16, 2026	Sold as noticed Sold 40,985 at $91.98 on Mar 16 · $3.8M Form 4	Filing · EDGAR
Feb 2, 2026	9,108 · ~$945K	Feb 2, 2026	Sold as noticed Sold 9,108 at $103.30 on Feb 2 · $941K Form 4	Filing · EDGAR
Mirum Pharmaceuticals MIRM · Morgan Stanley Smith Barney · 10b5-1 plan adopted Jan 23, 2024 · 1 notice
Jan 28, 2026	6,831 · ~$662K	Jan 26, 2026	Sold as noticed Sold 6,831 at $96.19 on Jan 26 · $657K Form 4	Filing · EDGAR
Mirum Pharmaceuticals MIRM · Morgan Stanley Smith Barney · 10b5-1 plan adopted Nov 22, 2024 · 3 notices
Aug 11, 2025	40,000 · ~$2.5M	Aug 11, 2025	Sold as noticed Sold 40,000 at $62.00 on Aug 11 · $2.5M Form 4	Filing · EDGAR
Aug 7, 2025	40,000 · ~$2.2M	Aug 7, 2025	Sold as noticed Sold 40,000 at $55.25 on Aug 7 · $2.2M Form 4	Filing · EDGAR
Mar 3, 2025	40,000 · ~$1.9M	Mar 3, 2025	Sold as noticed Sold 40,000 in 2 sales, Mar 3 to Mar 3 · $1.9M Form 4	Filing · EDGAR
Sales without a matching Form 144 · 10 sales No matching Form 144 found. Not every sale needs one: small sales and sales by people who are not affiliates are exempt.
—	—	—	Sold without notice Mirum Pharmaceuticals (MIRM): Sold 7,098 at $93.33 on Jan 22, 2026 · $662K	Filing · EDGAR
—	—	—	Sold without notice Mirum Pharmaceuticals (MIRM): Sold 27,279 at $44.21 on Mar 17, 2025 · $1.2M	Filing · EDGAR
—	—	—	Sold without notice Mirum Pharmaceuticals (MIRM): Sold 9,102 at $48.22 on Feb 3, 2025 · $439K	Filing · EDGAR
—	—	—	Sold without notice Mirum Pharmaceuticals (MIRM): Sold 6,837 at $47.92 on Jan 24, 2025 · $328K	Filing · EDGAR
—	—	—	Sold without notice Mirum Pharmaceuticals (MIRM): Sold 7,489 at $42.82 on Jan 7, 2025 · $321K	Filing · EDGAR
—	—	—	Sold without notice Mirum Pharmaceuticals (MIRM): Sold 6,013 at $26.19 on Feb 2, 2024 · $157K	Filing · EDGAR
—	—	—	Sold without notice Mirum Pharmaceuticals (MIRM): Sold 5,209 at $28.03 on Jan 8, 2024 · $146K	Filing · EDGAR
—	—	—	Sold without notice Mirum Pharmaceuticals (MIRM): Sold 5,498 at $25.65 on Jul 3, 2023 · $141K	Filing · EDGAR
—	—	—	Notice not machine-readable Mirum Pharmaceuticals (MIRM): Sold 5,159 at $20.62 on Jan 9, 2023 · $106K	Filing · EDGAR
—	—	—	Notice not machine-readable Mirum Pharmaceuticals (MIRM): Sold 3,672 at $19.26 on Oct 1, 2021 · $71K	Filing · EDGAR

Every transaction, by company

Each Form 3, 4 and 5 transaction in plain words, newest first.

How these figures work

Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.

Mirum Pharmaceuticals MIRM Chief executive officer · filings 2019 to 2026 · sold $27.6M · bought $294K · $24M noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
Nov 4, 2026	Option or RSU exercised or converted	+20,000	$2.94	$59K	226,637 direct	Filing · EDGAR
Nov 4, 2026	Sale under a 10b5-1 plan	−20,000	$90.00	$1.8M	206,637 direct	Filing · EDGAR
Nov 4, 2026	Option or RSU exercised or converted Employee Stock Option (right to buy)	−20,000			38,487 direct	Filing · EDGAR
Oct 6, 2026	Option or RSU exercised or converted	+5,305	$19.19	$102K	199,745 direct	Filing · EDGAR
Oct 6, 2026	Option or RSU exercised or converted	+6,892	$15.87	$109K	206,637 direct	Filing · EDGAR
Oct 6, 2026	Option or RSU exercised or converted Employee Stock Option (right to buy)	−5,305			169,695 direct	Filing · EDGAR
Oct 6, 2026	Option or RSU exercised or converted Employee Stock Option (right to buy)	−6,892			233,108 direct	Filing · EDGAR
Sep 1, 2026	Option or RSU exercised or converted	+30,000	$2.94	$88K	224,440 direct	Filing · EDGAR
Sep 1, 2026	Sale under a 10b5-1 plan	−8,312	$98.08	$815K	216,128 direct	Filing · EDGAR
Sep 1, 2026	Sale under a 10b5-1 plan	−21,688	$98.91	$2.1M	194,440 direct	Filing · EDGAR
Sep 1, 2026	Option or RSU exercised or converted Employee Stock Option (right to buy)	−30,000			58,487 direct	Filing · EDGAR
Aug 10, 2026	Option or RSU exercised or converted	+20,000	$2.94	$59K	214,309 direct	Filing · EDGAR
Aug 10, 2026	Sale under a 10b5-1 plan	−11,683	$98.51	$1.2M	202,626 direct	Filing · EDGAR
Aug 10, 2026	Sale under a 10b5-1 plan	−6,017	$99.25	$597K	196,609 direct	Filing · EDGAR
Aug 10, 2026	Sale under a 10b5-1 plan	−2,300	$100.14	$230K	194,309 direct	Filing · EDGAR
Aug 10, 2026	Option or RSU exercised or converted Employee Stock Option (right to buy)	−20,000			88,487 direct	Filing · EDGAR
Jul 6, 2026	Option or RSU exercised or converted	+20,000	$2.94	$59K	214,309 direct	Filing · EDGAR
Jul 6, 2026	Sale under a 10b5-1 plan	−12,134	$121.65	$1.5M	202,175 direct	Filing · EDGAR
Jul 6, 2026	Sale under a 10b5-1 plan	−4,181	$122.34	$512K	197,994 direct	Filing · EDGAR
Jul 6, 2026	Sale under a 10b5-1 plan	−1,975	$123.74	$244K	196,019 direct	Filing · EDGAR
Jul 6, 2026	Sale under a 10b5-1 plan	−1,710	$124.79	$213K	194,309 direct	Filing · EDGAR
Jul 6, 2026	Option or RSU exercised or converted Employee Stock Option (right to buy)	−20,000			108,487 direct	Filing · EDGAR
Jun 1, 2026	Option or RSU exercised or converted	+30,000	$2.94	$88K	224,309 direct	Filing · EDGAR
Jun 1, 2026	Sale under a 10b5-1 plan	−2,602	$94.64	$246K	221,707 direct	Filing · EDGAR
Jun 1, 2026	Sale under a 10b5-1 plan	−16,595	$95.34	$1.6M	205,112 direct	Filing · EDGAR
Jun 1, 2026	Sale under a 10b5-1 plan	−6,926	$96.15	$666K	198,186 direct	Filing · EDGAR
Jun 1, 2026	Sale under a 10b5-1 plan	−1,973	$97.56	$192K	196,213 direct	Filing · EDGAR
Jun 1, 2026	Sale under a 10b5-1 plan	−1,021	$98.20	$100K	195,192 direct	Filing · EDGAR
Jun 1, 2026	Sale under a 10b5-1 plan	−883	$99.66	$88K	194,309 direct	Filing · EDGAR
Jun 1, 2026	Option or RSU exercised or converted Employee Stock Option (right to buy)	−30,000			128,487 direct	Filing · EDGAR
Mar 16, 2026	Open-market or private sale	−40,985	$91.98	$3.8M	194,309 direct	Filing · EDGAR
Mar 15, 2026	Option or RSU exercised or converted	+25,000			185,294 direct	Filing · EDGAR
Mar 15, 2026	Option or RSU exercised or converted	+50,000			235,294 direct	Filing · EDGAR
Mar 15, 2026	Option or RSU exercised or converted Performance Restricted Stock Units	−25,000			0 direct	Filing · EDGAR
Mar 15, 2026	Option or RSU exercised or converted Performance Restricted Stock Units	−50,000			25,000 direct	Filing · EDGAR
Feb 2, 2026	Open-market or private sale	−9,108	$103.30	$941K	160,294 direct	Filing · EDGAR
Jan 28, 2026	Grant or award from the company Stock Option (right to buy)	+67,000			67,000 direct	Filing · EDGAR
Jan 28, 2026	Grant or award from the company Restricted Stock Units	+43,500			43,500 direct	Filing · EDGAR
Jan 28, 2026	Grant or award from the company Performance Restricted Stock Units	+75,000			75,000 direct	Filing · EDGAR
Jan 26, 2026	Open-market or private sale	−6,831	$96.19	$657K	169,402 direct	Filing · EDGAR
Jan 23, 2026	Option or RSU exercised or converted	+12,500			176,233 direct	Filing · EDGAR
Jan 23, 2026	Option or RSU exercised or converted Restricted Stock Units	−12,500			12,500 direct	Filing · EDGAR
Jan 22, 2026	Open-market or private sale	−7,098	$93.33	$662K	163,733 direct	Filing · EDGAR
Jan 21, 2026	Option or RSU exercised or converted	+12,797			170,831 direct	Filing · EDGAR
Jan 21, 2026	Option or RSU exercised or converted Restricted Stock Units	−12,797			25,593 direct	Filing · EDGAR
Dec 31, 2025	Gift	−21,070			187,500 By The Peetz Family Trust	Filing · EDGAR
Nov 18, 2025	Option or RSU exercised or converted	+19,133	$19.24	$368K	158,034 direct	Filing · EDGAR
Nov 18, 2025	Option or RSU exercised or converted Employee Stock Option (right to buy)	−19,133			150,867 direct	Filing · EDGAR
Aug 11, 2025	Option or RSU exercised or converted	+40,000	$2.94	$117K	178,641 direct	Filing · EDGAR
Aug 11, 2025	Sale under a 10b5-1 plan	−40,000	$62.00	$2.5M	138,641 direct	Filing · EDGAR
Aug 11, 2025	Option or RSU exercised or converted Employee Stock Option (right to buy)	−40,000			158,487 direct	Filing · EDGAR
Aug 7, 2025	Option or RSU exercised or converted	+40,000	$2.94	$117K	178,641 direct	Filing · EDGAR
Aug 7, 2025	Sale under a 10b5-1 plan	−40,000	$55.25	$2.2M	138,641 direct	Filing · EDGAR
Aug 7, 2025	Option or RSU exercised or converted Employee Stock Option (right to buy)	−40,000			198,487 direct	Filing · EDGAR
Mar 17, 2025	Open-market or private sale	−27,279	$44.21	$1.2M	138,641 direct	Filing · EDGAR
Mar 15, 2025	Option or RSU exercised or converted	+50,000			165,920 direct	Filing · EDGAR
Mar 15, 2025	Option or RSU exercised or converted Performance Restricted Stock Units	−50,000			25,000 direct	Filing · EDGAR
Mar 3, 2025	Option or RSU exercised or converted	+40,000	$2.94	$117K	155,920 direct	Filing · EDGAR
Mar 3, 2025	Sale under a 10b5-1 plan	−19,392	$46.61	$904K	136,528 direct	Filing · EDGAR
Mar 3, 2025	Sale under a 10b5-1 plan	−20,608	$47.19	$972K	115,920 direct	Filing · EDGAR

38 earlier transactions are in the filing list below.

Arcutis Biotherapeutics ARQT Director · filings 2026 to 2026

Date	Transaction	Shares	Held after	Source
Jul 15, 2026	Grant or award from the company	+4,315	4,315 direct	Filing · EDGAR
Jul 15, 2026	Grant or award from the company Stock Option (right to buy)	+21,486	21,486 direct	Filing · EDGAR
Jul 15, 2026	Grant or award from the company Stock Option (right to buy)	+13,010	13,010 direct	Filing · EDGAR

Alpine Immune Sciences Director · filings 2018 to 2024 · bought $19K

Date	Transaction	Shares	Price	Value	Held after	Source
May 20, 2024	Returned to the company	−1,900	$0.00	$2	0 Christopher Peetz & Christine Peetz TR UA 02/15/2017 The Peetz Living Trust	Filing · EDGAR
May 20, 2024	Returned to the company Stock Option (Right to buy)	−7,650			0 direct	Filing · EDGAR
May 20, 2024	Returned to the company Stock Option (Right to buy)	−7,650			0 direct	Filing · EDGAR
May 20, 2024	Returned to the company Stock Option (Right to buy)	−7,650			0 direct	Filing · EDGAR
May 20, 2024	Returned to the company Stock Option (Right to buy)	−7,650			0 direct	Filing · EDGAR
May 20, 2024	Returned to the company Stock Option (Right to buy)	−10,000			0 direct	Filing · EDGAR
May 20, 2024	Returned to the company Stock Option (Right to buy)	−10,000			0 direct	Filing · EDGAR
May 20, 2024	Returned to the company Stock Option (Right to buy)	−17,500			0 direct	Filing · EDGAR
Jan 2, 2024	Grant or award from the company Stock Option (Right to buy)	+17,500			17,500 direct	Filing · EDGAR
Jan 3, 2023	Grant or award from the company Stock Option (Right to buy)	+10,000			10,000 direct	Filing · EDGAR
Jan 3, 2022	Grant or award from the company Stock Option (Right to buy)	+10,000			10,000 direct	Filing · EDGAR
Sep 23, 2021	Open-market or private purchase	+1,900	$10.17	$19K	1,900 Christopher Peetz and Christine Peetz TR UA 02/15/2017 The Peetz Living Trust	Filing · EDGAR
Sep 23, 2021	Open-market or private sale	+1,900	$10.17	$19K	1,900 Christopher Peetz & Christine Peetz TR UA 02/15/2017 The Peetz Living Trust	Filing · EDGAR
Jan 4, 2021	Grant or award from the company Stock Option (Right to buy)	+7,650			7,650 direct	Filing · EDGAR
Jan 2, 2020	Grant or award from the company Stock Option (Right to buy)	+7,650			7,650 direct	Filing · EDGAR
Jan 2, 2019	Grant or award from the company Stock Option (Right to buy)	+7,650			7,650 direct	Filing · EDGAR
Apr 20, 2018	Grant or award from the company Stock Option (right to buy)	+7,650			7,650 direct	Filing · EDGAR

Tobira Therapeutics Chief Financial Officer · filings 2015 to 2016

Date	Transaction	Shares	Held after	Source
Nov 1, 2016	Returned to the company Employee Stock Option (Right to Buy)	−68,732	0 direct	Filing · EDGAR
Nov 1, 2016	Returned to the company Employee Stock Option (Right to Buy)	−31,091	0 direct	Filing · EDGAR
Nov 1, 2016	Returned to the company Employee Stock Option (Right to Buy)	−85,000	0 direct	Filing · EDGAR
Nov 1, 2016	Returned to the company Employee Stock Option (Right to Buy)	−101,000	0 direct	Filing · EDGAR
Jan 12, 2016	Grant or award from the company Stock Options (right to buy)	+101,000	101,000 direct	Filing · EDGAR
May 15, 2015	Grant or award from the company Stock Options (right to buy)	+85,000	85,000 direct	Filing · EDGAR
May 6, 2015	Grant or award from the company Stock Options (right to buy)	+68,732	68,732 direct	Filing · EDGAR
May 6, 2015	Grant or award from the company Stock Options	+31,091	99,823 direct	Filing · EDGAR

All 72 Forms 3, 4, 5 and 144

Filed	Form	Company	Links
Nov 4, 2026	Form 144	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Nov 4, 2026	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Oct 6, 2026	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Sep 3, 2026	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Sep 1, 2026	Form 144	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Aug 11, 2026	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Aug 10, 2026	Form 144	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jul 17, 2026	Form 4	Arcutis Biotherapeutics ARQT	Filing · EDGAR
Jul 17, 2026	Form 3	Arcutis Biotherapeutics ARQT	Filing · EDGAR
Jul 8, 2026	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jul 6, 2026	Form 144	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jun 2, 2026	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jun 1, 2026	Form 144	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Mar 17, 2026	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Mar 17, 2026	Form 144	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Feb 3, 2026	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Feb 2, 2026	Form 144	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jan 30, 2026	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jan 28, 2026	Form 144	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jan 27, 2026	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jan 23, 2026	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jan 2, 2026	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Nov 20, 2025	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Aug 12, 2025	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Aug 11, 2025	Form 144	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Aug 8, 2025	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Aug 7, 2025	Form 144	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Mar 18, 2025	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Mar 4, 2025	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Mar 3, 2025	Form 144	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Feb 4, 2025	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jan 27, 2025	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jan 23, 2025	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jan 8, 2025	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Nov 14, 2024	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jul 24, 2024	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
May 20, 2024	Form 4	Alpine Immune Sciences	Filing · EDGAR
May 16, 2024	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Mar 18, 2024	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Feb 5, 2024	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jan 25, 2024	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jan 9, 2024	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jan 4, 2024	Form 4	Alpine Immune Sciences	Filing · EDGAR
Jul 5, 2023	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
May 19, 2023	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Feb 2, 2023	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jan 5, 2023	Form 4	Alpine Immune Sciences	Filing · EDGAR
Nov 14, 2022	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
May 12, 2022	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jan 7, 2022	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jan 4, 2022	Form 4	Alpine Immune Sciences	Filing · EDGAR
Nov 29, 2021	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Oct 1, 2021	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Sep 27, 2021	Form 4/A	Alpine Immune Sciences	Filing · EDGAR
Sep 24, 2021	Form 4	Alpine Immune Sciences	Filing · EDGAR
May 12, 2021	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jan 11, 2021	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jan 5, 2021	Form 4	Alpine Immune Sciences	Filing · EDGAR
Dec 28, 2020	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Nov 12, 2020	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jan 14, 2020	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jan 6, 2020	Form 4	Alpine Immune Sciences	Filing · EDGAR
Sep 10, 2019	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jul 17, 2019	Form 3	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jan 4, 2019	Form 4	Alpine Immune Sciences	Filing · EDGAR
Apr 24, 2018	Form 4	Alpine Immune Sciences	Filing · EDGAR
Apr 24, 2018	Form 3	Alpine Immune Sciences	Filing · EDGAR
Nov 3, 2016	Form 4	Tobira Therapeutics	Filing · EDGAR
Jan 14, 2016	Form 4	Tobira Therapeutics	Filing · EDGAR
May 18, 2015	Form 4	Tobira Therapeutics	Filing · EDGAR
May 6, 2015	Form 4	Tobira Therapeutics	Filing · EDGAR
May 6, 2015	Form 3	Tobira Therapeutics	Filing · EDGAR

Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.